Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT00251199
NCT00251199CompletedPhase 1

A Phase 1b Viral Kinetic Study of VX-950 and Peginterferon in Hepatitis C

Vertex Pharmaceuticals Incorporated2 sites in 2 countries20 target enrollmentStarted: October 2005Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Drugs

Trial Snapshot

Phase
Phase 1
Status
Completed
Enrollment
20
Locations
2
Primary Endpoint
Viral kinetics
Study OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

VX-950 is an investigational drug , which is being tested in combination with a known treatment for hepatitis C, peginterferon.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Masking
Double

Eligibility Criteria

Ages
18 Years to 60 Years (Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •infected with Hepatitis C virus

Exclusion Criteria

  • •contraindications to peginterferon therapy

Outcomes

Primary Outcomes

Viral kinetics

Secondary Outcomes

  • Assess the safety of VX-950 in combination with peginterferon

Investigators

Sponsor Class
Industry

Study Sites (2)

Loading locations...

Similar Trials

Completed
Phase 1
A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation of VX-993Pain
NCT06508762Vertex Pharmaceuticals Incorporated24
Active, not recruiting
Phase 2
The Combination of Venetoclax and Obinutuzumab in People With Chronic Lymphocytic Leukemia (CLL)Chronic Lymphocytic Leukemia (CLL)
NCT04447768Memorial Sloan Kettering Cancer Center100
Terminated
Phase 1
A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Multiple Doses of Orally Administered JNJ-53718678 in Infants Hospitalized With Respiratory Syncytial Virus (RSV) InfectionRespiratory Syncytial Virus InfectionsVirus Diseases
NCT02593851Janssen Sciences Ireland UC45
Completed
Phase 1
Evaluating the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of the Monoclonal Antibody PGT121.414.LS Administered Alone and in Combination With VRC07-523LS Via Intravenous or Subcutaneous Infusions in Healthy, HIV-uninfected Adult ParticipantsHIV Infections
NCT04212091National Institute of Allergy and Infectious Diseases (NIAID)33
Recruiting
Phase 2
Clinical Study Protocol of Venetoclax Combined With Azacitidine and Harringtonine in the Treatment of sAMLSecondary Acute Myeloid Leukemia
NCT05513131The First Affiliated Hospital with Nanjing Medical University30
VX-950 and Peginterferon for Hepatitis C | Clinical Trial